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In fact, cardiovascular disease is accountable for half of all fatalities in endstage renal disease, which, despite improvements in care over the last 2 decades, has an overall mortality of ≈15% to 20% per year. 2, 3 Chronic kidney disease is a prevalent and challenging disorder affecting 14.8% of the adult general population in the United States. 2 Also, the incidence of end-stage renal disease remains high, with 124 114 newly reported cases receiving renal replacement therapy in the United States in 2015, 87% of which were treated by hemodialysis. 2 Although cardiovascular and chronic kidney disease share many risk factors such as diabetes mellitus and hypertension, which may explain their frequent association, it recently became clear that the increased cardiovascular risk in patients with chronic kidney disease is at least partly mediated by factors specifically linked to renal insufficiency. 1 For instance, isolated impairment in renal function elevates the risk for future coronary events, which equals or exceeds the risk of traditional risk factors. 4 However, statins fail to attenuate cardiovascular mortality despite a significant low-density lipoprotein cholesterol reduction in patients on hemodialysis. 5 Mechanisms that enhance vascular inflammation in chronic kidney disease may include modification of low-density lipoprotein or fibroblast growth factor 23 signaling, which contributes to vascular calcification. 1 Overall, the reason for rapidly progressing atherosclerosis in patients with chronic kidney disease remains incompletely understood.
In recent years, the toxicity of uremic retention solutes has been increasingly recognized. 6 More than 150 molecules have been cataloged so far. 7 Although hemodialysis removes the majority of small-sized and nonprotein-bound solutes, binding to albumin (66 kDa) impedes the diffusion across the membrane pores, which only allow passage up to a size of ≈20 kDa. 7 Indoxyl sulfate, one of the most studied protein-bound uremic toxins, is independently associated with cardiovascular events. 8, 9 Other studies also suggest a role of indoxyl sulfate in the progression of renal fibrosis, bone remodeling, and neurological impairment. 6 Colon microbiota convert dietary tryptophan to indole, which is further processed in the liver, and cleared via secretion in the proximal tubules involving organic anion transporters, a mechanism compromised in chronic kidney disease. 7 Because indoxyl sulfate is bound 90% to albumin, it readily accumulates despite regular hemodialysis. 10 In this issue of Circulation, Nakano and colleagues 11 demonstrate how indoxyl sulfate connects chronic kidney disease with vascular inflammation and atherosclerosis. Macrophages essentially contribute to the progression of atherosclerotic lesions. 12 In this study, the authors report that indoxyl sulfate induces the expression of interleukin 1-β and other inflammatory cytokines in human primary mac-rophages in a toll-like receptor-independent manner. The authors describe that macrophages express several organic anion transporters (OATs) as well as OAT polypeptides. Using small interfering RNA-mediated silencing followed by high-performance liquid chromatography, they detected uptake of indoxyl sulfate into macrophages via OAT polypeptide P2B1. This finding was replicated when OAT polypeptide inhibitors such as rifampicin or cyclosporin were used. Using a tandem mass tagging quantitative proteomics approach followed by pathway analysis, the authors found Notch signaling highly enriched in indoxyl sulfate-treated macrophages. Notch receptors are transmembrane proteins with a role in development and cardiovascular disease. Indoxyl sulfate induced an early increase in δ-like ligand 4 (Dll4). Dll4 induces cleavage of the intracellular domain of Notch1, which then functions as a transcriptional regulator. Nakano et al 11 report accumulation of intracellular domain-Notch1 and enhanced luciferase activity of an intracellular domain-sensitive gene in human primary macrophages, confirming Notch1 signaling. It is interesting to note the authors noticed that indoxyl sulfate did not induce Dll4 in all macrophages at similar levels. To understand the heterogeneous response in greater detail, the authors conducted mass cytometry of cultured macrophages, followed by cluster analyses. The observed macrophage heterogeneity is remarkable and in line with the recent understanding that macrophages are highly dynamic cells that can adopt and display multiple facets at a time, rather than just respond unidimensionally to a single stimulus. 12 Next, the authors explored the mechanism of how indoxyl sulfate increases levels of the Notch1 ligand Dll4. Although transcriptional changes of Dll4 occurred with some delay, indoxyl sulfate inhibited the ubiquitinproteasome pathway, an endogenous protein disposal machinery. Ubiquitin-specific peptidase 5, a deubiquitinating enzyme that controls the ubiquitin-proteasome pathway activity, mediated the indoxyl sulfate-induced inhibition, as shown by the silencing of different ubiquitin-specific peptidase enzymes. Thus, increased Dll4 levels rely on impaired breakdown rather than on increased production.
Although the in vitro experiments provide mechanistic depth of how indoxyl sulfate may activate macrophages, studies investigating macrophage behavior in vitro are generally hampered by their artificial behavior in culture and do not necessarily reflect how they react in vivo. Therefore, the follow-up experiments in mice add great value to the conclusions of this study. Lipid nanoparticles C12-200 are an efficient delivery vehicle for in vivo RNA interference in myeloid cells. 13 Nanoparticles loaded with OAT polypeptide P2B1 small interfering RNA achieved a silencing efficacy of >70% and significantly reduced production of inflammatory cytokines in peritoneal macrophages. A similar effect was observed if mice received Dll4 antibody. Because injection of indoxyl sulfate is a rather selective approach, the authors then used a model of renal failure. A 5/6 ne- Macrophages in atherosclerotic lesions take up indoxyl sulfate via OATP2B1. Indoxyl sulfate increases USP5, which inhibits the ubiquitin proteasome pathway. Dll4 levels increase because of impaired degradation and activate NOTCH receptors on macrophages in proximity. NOTCH-ICD translocates into the nucleus and induces the transcription of proinflammatory cytokines, which further aggravate atherosclerotic lesion development. Dll4 indicates δ-like ligand 4; ICD, intracellular domain; Il1β, interleukin 1-β; MCP1, monocyte chemoattractant protein 1; OATP2B1, organic anion transporting polypeptide P2B1; UPP, ubiquitin proteasome pathway; and USP5, ubiquitinspecific peptidase 5. phrectomy in atherosclerotic mice increased Notch-intracellular domain and Dll4 expression in plaque macrophages, indicating enhanced Notch activity, as assessed by immunofluorescence. Treatment with an antibody against Dll4 that was administered while mice were fed a high-fat diet attenuated atherosclerotic lesion development, reduced vascular inflammatory cytokine production, decreased accumulation of macrophages, and lowered markers for vascular calcification. Finally, the authors tested the effects of nanoparticle-enabled small interfering RNA silencing of OAT polypeptide P2B1 and Dll4 on lesion development in mice. Silencing of OAT polypeptide P2B1 or Dll4 attenuated plaque progression and aortic inflammatory cytokine expression.
This study provides novel, mechanistic in vivo data on how uremic toxins may drive the progression of atherosclerosis in mice (Figure) . In addition, the authors developed treatment options directly targeting toxin uptake or receptor ligands. The comprehensive data set provided by Nakano and colleagues 11 convincingly demonstrates how indoxyl sulfate activates plaque macrophages. Because existing strategies against coronary artery disease often fail in the setting of end-stage renal disease, the discovered molecular link may help to develop strategies targeting macrophage activation in this context. Considering the high number of uremic retention solutes that evade clearance via hemodialysis in patients with end-stage renal disease, it is likely that this effect is not confined to indoxyl sulfate. 10 Identifying additional toxins, their potency and biological properties, and whether their uptake is mediated via OATs will be important. Generally, RNA interference therapy in humans is feasible, as recently demonstrated for the RNA interference therapeutic patisiran in patients with amyloidosis.
14 Because indoxyl sulfate triggered the release of interleukin 1-β, the use of canakinumab may be another therapeutic approach to limit vascular inflammation, while keeping in mind the increased susceptibility to infection in patients undergoing hemodialysis. 15 Indoxyl sulfate may alter other cell types relevant for the pathogenesis of atherosclerosis in chronic kidney disease. In fact, indoxyl sulfate upregulates adhesion molecules on cultured endothelial cells and induces proliferation of vascular smooth muscle cells. 6 Effects on myeloid progenitor cells remain to be elucidated. In this regard, it remains unclear whether transient episodes of renal failure will suffice to alter macrophage activation in pre-existing lesions or lead to enhanced bone marrow activation, which then supplies more inflammatory cells to the vasculature. Do plaque macrophages acquire an epigenetic memory of recent uremic episodes? Are similar effects occurring in other macrophages, including resident macrophages such as microglia, cardiac macrophages, or macrophages in the bone marrow? Nakano and colleagues 11 provide important new information on how chronic kidney disease enhances vascular inflammation. These data provide a rationale for how endstage renal disease accelerates atherosclerosis. 
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